Cancer immunotherapy: Current applications and challenges

• Published in: Cancer letters Vol. 480; pp. 1 - 3
• Main Authors: Sun, Jin-Yu, Lu, Xiao-Jie
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 28-06-2020; Elsevier Limited
• Subjects: Antigens; Antineoplastic Agents, Immunological - pharmacology; Antineoplastic Agents, Immunological - therapeutic use; Biomarkers; Cancer; Cancer immunotherapy; Cancer therapies; Chemotherapy; Clinical trials; Clinical Trials as Topic; CRISPR; Dendritic cells; Effector cells; Genomes; Humans; Immunoregulation; Immunotherapy; Immunotherapy - adverse effects; Immunotherapy - methods; Lymphocytes; Lymphocytes T; Monoclonal antibodies; Natural killer cells; Neoplasms - immunology; Neoplasms - therapy; PD-1 protein; PD-L1 protein; Radiation therapy; Suppressor cells; T cell receptors; Tumor Microenvironment - immunology
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2020.03.024

Only about 13% patients are estimated to exhibit a positive response to ICIs therapies [7], and patients with clinical responses may ultimately experience cancer progression after a few years due to primary or acquired resistance [8]. [...]a substantial percentage of cancer patients receiving immunotherapies will develop immune-related adverse events (irAEs) [9], with an incidence of 72% in ipilimumab monotherapy [10] or 66% in anti–PD-1/anti–PD-L1 monotherapy [11]. [31] discuss the biological function of TIME from the aspect of tumor-antagonizing (effector T cells, natural killer cells, dendritic cells, etc.) and tumor-promoting immune cells (regulatory T cells and myeloid-derived suppressor cells), as well as their roles in cancer immunotherapy. [...]we would like to express our sincere appreciation to all the authors contributing their knowledge and expertise to this special issue.Funding This work was supported by the National Natural Science Foundation of China (Grant No. 81772596 to X-JL).